ADIL vs AEON

Adial Pharmaceuticals, Inc vs AEON Biopharma, Inc. — Valuation Comparison 2026

ADIL

Biotechnology
Adial Pharmaceuticals, Inc
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$2.53
Last close
Models
7/13
Active
VS

AEON

Biotechnology
AEON Biopharma, Inc.
Quality
3.3
out of 10
Value Trap
18
SAFE
Price
$0.72
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ADIL Fair ValueADIL Upside AEON Fair ValueAEON Upside
Bayesian DCF Intrinsic $1.85 -27.0% $0.12 -86.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.33 -78.5% $0.21 -76.4%
Dynamic NAV Asset-Based $1.58 -37.4% $0.02 -97.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADIL vs AEON — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADIL vs AEON — Which Stock Is More Undervalued?

ADIL scores higher with a 4.4/10 quality rating vs AEON's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Adial Pharmaceuticals, Inc (ADIL) and AEON Biopharma, Inc. (AEON) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADIL currently trades at $2.53 with a QOC of 4.4/10, while AEON trades at $0.72 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).